 |
|
Oral Famciclovir for Suppression of Recurrent Genital Herpes Simplex Virus Infection in WomenA Multicenter, Double-Blind, Placebo-Controlled Trial
Gregory J. Mertz, MD;
Mark O. Loveless, MD;
Myron J. Levin, MD;
Stephen J. Kraus, MD;
Sandra L. Fowler, MD;
Diane Goade, MD;
Stephen K. Tyring, MD, PhD
Arch Intern Med. 1997;157(3):343-349.
Abstract
Objective
To evaluate the efficacy and safety of oral famciclovir in the suppression of genital herpes.
Methods
In this randomized, double-blind, placebo-controlled trial that was performed at 11 university and 9 private ambulatory care referral centers, 375 women who were 18 years of age or older and had a history of 6 or more episodes of genital herpes during 12 of the last 24 months in the absence of suppressive therapy were treated for 4 months with oral famciclovir, 125 mg once daily or twice daily, 250 mg once daily or twice daily, 500 mg once daily, or placebo. The primary outcome measures included the time to first clinically and virologically confirmed recurrences, and safety as measured by clinical laboratory tests and adverse experiences.
Results
The median time to first recurrence was 82 days in the placebo group, 114 days in those receiving famciclovir, 125 mg once daily, and more than 120 days in the other treatment groups. When compared with placebo recipients, the time to the first clinical recurrence was significantly prolonged in subjects who received famciclovir, 125 mg twice daily (hazard ratio, 1.8; 95% confidence interval, 1.0-3.0; P=.03), and in those who received famciclovir, 250 mg twice daily (hazard ratio, 3.6; 95% confidence interval, 1.9-6.9; P<.001). Treatment was well tolerated, and there was no evidence of emergence of resistance during or after suppressive famciclovir therapy.
Conclusions
Oral famciclovir, 250 mg, given twice daily for 4 months is an effective, well-tolerated treatment for the suppression of genital herpes in women with frequent recurrences, but single daily doses produced less complete suppression of genital herpes.
Arch Intern Med. 1997;157:343-349
Author Affiliations
From the Department of Internal Medicine, School of Medicine, University of New Mexico Health Sciences Center, Albuquerque (Drs Mertz and Goade); the Department of Medicine, Oregon Health Sciences University, Portland (Dr Loveless); the Department of Pediatrics, University of Colorado School of Medicine, Denver (Dr Levin); Georgia Clinical Research Center, Atlanta (Dr Kraus); the Department of Pediatrics, Medical University of South Carolina, Charleston (Dr Fowler); and the University of Texas Medical Branch at Galveston (Dr Tyring). Members of the Collaborative Famciclovir Genital Herpes Research Group are listed on page 346.
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
The Treatment of Herpes Simplex Infections: An Evidence-Based Review
Cernik et al.
Arch Intern Med 2008;168:1137-1144.
ABSTRACT
| FULL TEXT
Recurrent Benign Lymphocytic Meningitis
Shalabi and Whitley
Clinical Infectious Diseases 2006;43:1194-1197.
ABSTRACT
| FULL TEXT
Patient satisfaction with care for genital herpes: insights from a global survey
Patrick et al.
Sex. Transm. Infect. 2004;80:192-197.
ABSTRACT
| FULL TEXT
Famciclovir Suppression of Asymptomatic and Symptomatic Recurrent Anogenital Herpes Simplex Virus Shedding in Women: A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group, Single-Center Trial
Sacks
The Journal of Infectious Disease 2004;189:1341-1347.
ABSTRACT
| FULL TEXT
Susceptibility of Herpes Simplex Virus Isolates to Nucleoside Analogues and the Proportion of Nucleoside-Resistant Variants after Repeated Topical Application of Penciclovir to Recurrent Herpes Labialis
Shin et al.
The Journal of Infectious Disease 2003;187:1241-1245.
ABSTRACT
| FULL TEXT
Challenges in Genital Herpes Simplex Virus Management
Corey
The Journal of Infectious Disease 2002;186:S29-S33.
ABSTRACT
| FULL TEXT
Progress in Meeting Today's Demands in Genital Herpes: An Overview of Current Management
Patel
The Journal of Infectious Disease 2002;186:S47-S56.
ABSTRACT
| FULL TEXT
Imiquimod 5-Percent Cream Does Not Alter the Natural History of Recurrent Herpes Genitalis: a Phase II, Randomized, Double-Blind, Placebo-Controlled Study
Schacker et al.
Antimicrob. Agents Chemother. 2002;46:3243-3248.
ABSTRACT
| FULL TEXT
Application of a Topical Immune Response Modifier, Resiquimod Gel, to Modify the Recurrence Rate of Recurrent Genital Herpes: A Pilot Study
Spruance et al.
The Journal of Infectious Disease 2001;184:196-200.
ABSTRACT
| FULL TEXT
Effects of Antiviral Usage on Transmission Dynamics of Herpes Simplex Virus Type 1 and on Antiviral Resistance: Predictions of Mathematical Models
Lipsitch et al.
Antimicrob. Agents Chemother. 2000;44:2824-2835.
ABSTRACT
| FULL TEXT
Genital Herpes: Review of the Epidemic and Potential Use of Type-Specific Serology
Ashley and Wald
Clin. Microbiol. Rev. 1999;12:1-8.
ABSTRACT
| FULL TEXT
Update on drugs for herpes zoster and genital herpes
DTB 1998;36:77-79.
ABSTRACT
| FULL TEXT
Oral Famciclovir for the Suppression of Recurrent Genital Herpes: A Randomized Controlled Trial
Diaz-Mitoma et al.
JAMA 1998;280:887-892.
ABSTRACT
| FULL TEXT
FAMCICLOVIR FOR RECURRENT GENITAL HERPES SIMPLEX INFECTIONS IN WOMEN
JWatch General 1997;1997:4-4.
FULL TEXT
|
